Form 4: BioXcel Therapeutics CSO Executes RSU Conversion

Chief Scientific Officer Frank Yocca acquired 35 shares of BioXcel Therapeutics common stock through the vesting of restricted stock units.

Summary

• Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics, Inc., converted 35 Restricted Stock Units (RSUs) into common stock.
• The transaction occurred on June 15, 2026.
• Following the transaction, the reporting person holds 26,210 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event related to executive compensation, having no material impact on the company's financial or operational outlook.

Positives

• The transaction reflects the ongoing vesting of equity compensation, aligning the interests of the Chief Scientific Officer with shareholders.

Negatives

• None identified.

Risks

• The reporting person's continued ownership is subject to the risks associated with the company's clinical development pipeline and financial stability.

Future Outlook

The filing does not provide forward-looking guidance regarding company performance or financial outlook.

Industry Context

StockSavvy.ai notes that routine RSU vesting for executive officers is a standard component of compensation packages in the biotechnology sector and generally does not signal a change in corporate strategy or insider sentiment.

Comparison to Industry Standards

• The transaction is consistent with standard equity compensation practices for C-suite executives in mid-cap biotechnology firms.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity compensation event.

Next Steps

• Continued vesting of remaining RSUs according to the established schedule.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, Form 4, Insider Transaction, Restricted Stock Units, Chief Scientific Officer